Commonwealth Equity Services
INSY

Commonwealth Equity Services’s Insys Therapeutics, Inc. INSY Stock Holding History

Commonwealth Equity Services’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15,045
Closed -$69K – 2846
2019
Q1 		$69K Sell
15,045
-311
-2% -$1.47K ﹤0.01% 2643
2018
Q4 		$53K Buy
15,356
+144
+0.9% +$1K ﹤0.01% 2563
2018
Q3 		$153K Buy
15,212
+1,580
+12% +$12.6K ﹤0.01% 2571
2018
Q2 		$99K Buy
13,632
+1,043
+8% +$7.27K ﹤0.01% 2608
2018
Q1 		$76K Buy
+12,589
New +$104K ﹤0.01% 2568
2017
Q1 		– Sell
-11,653
Closed -$107K – 2501
2016
Q4 		$107K Buy
+11,653
New +$132K ﹤0.01% 2185

Other funds holding INSY

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Commonwealth Equity Services's INSY Position: Q2 2019 in Review

Commonwealth Equity Services sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 15,045 shares — an estimated $69K sold.

Commonwealth Equity Services first reported a position in INSY in Q4 2016 and held it in 6 quarters. The position peaked at $153K in Q3 2018. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • Commonwealth Equity Services reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Commonwealth Equity Services sold 15,045 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $69K.
  • Commonwealth Equity Services first reported a position in Insys Therapeutics, Inc. in Q4 2016 and held it in 6 quarters.
  • Commonwealth Equity Services's Insys Therapeutics, Inc. position peaked at $153K in Q3 2018.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Commonwealth Equity Services's 13F filing for Q2 2019, filed 19 Jul 2019.